Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
12 Maio 2021 - 08:30AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for respiratory disease, allergy and opioid overdose,
today announced that it will host an investor conference call on
Monday, May 17, 2021 at 2 p.m. Pacific Time to discuss its
financial and operating results for the first quarter of 2021 as
well as provide a business update. The company’s press release
concerning its first quarter 2021 financial results will be
available after 1 p.m. Pacific Time on May 17, 2021 and on its
website at www.adamispharmaceuticals.com, and the company also
expects to file its quarterly report on Form 10-Q for the quarter
ended March 31, 2021 on that date.
Event: Adamis Pharmaceuticals First Quarter 2021
Financial Results Conference CallDate: Monday, May 17, 2021Time: 2
p.m. PT (5 p.m. ET)U.S. Dial-in (Toll Free):
1-877-300-8521TOLL/International Dial-in: 1-412-317-6026Conference
ID: 10156419
Dennis J. Carlo, Ph.D., President and CEO of
Adamis, will host the call along with other members of the
management team. The call is open to the public and will provide an
update on recent developments, events that have taken place during
the quarter, and certain target milestones and goals for future
periods. Forward-looking statements concerning expectations
regarding future company performance may be made during the
conference call.
A live audio webcast of the conference call will
also be available via this link –
http://public.viavid.com/index.php?id=144941, with
a replay available shortly after the live event.
About Adamis
Pharmaceuticals
Adamis Pharmaceuticals Corporation is a
specialty biopharmaceutical company primarily focused on developing
and commercializing products in various therapeutic areas,
including allergy, opioid overdose, respiratory and inflammatory
disease. The company’s SYMJEPI® (epinephrine) Injection products
are approved by the FDA for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. In addition to its
naloxone injection product candidate, ZIMHITM, Adamis is developing
additional products, including treatments for acute respiratory
diseases, such as COVID-19, influenza, asthma and COPD. The
company’s subsidiary, US Compounding Inc., compounds sterile
prescription drugs, and certain nonsterile drugs for human and
veterinary use by hospitals, clinics, surgery centers, and vet
clinics throughout most of the United States. For additional
information about Adamis Pharmaceuticals, please visit
www.adamispharmaceuticals.com.
Contact:
Adamis Investor Relations Robert UhlManaging
DirectorWestwicke ICR619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024